Leap Therapeutics: 2 Cancer Trials Disappoint, But There Is A Silver Lining
Leap Therapeutics, Inc.'s DKN-01 trial results show mixed outcomes in cancer treatment, prompting potential future funding ...
Too Old to Operate6h
Impact of Antibiotics on Immune Checkpoint Inhibitor Efficacy
The following is a summary of “Antibiotics use decreases survival in cutaneous squamous cell carcinoma patients receiving ...
clinicaladvisor.com4h
Enhertu Approved for HR+, HER2-Low/Ultralow Metastatic Breast Cancer
Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...
Too Old to Operate2d
FLOT Chemotherapy Improves Overall Survival in Esophageal Adenocarcinoma
The following is a summary of “Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer,” published ...
Targeted Oncology1h
ARANOTE Features Significant rPFS Benefit of Darolutamide/ADT in mHSPC
In a live event, Vinay Minocha, MD, discusses the addition of darolutamide to androgen deprivation therapy for in patients ...
HealthDay on MSN4d
Lower Dexamethasone Dose Does Not Impair Survival in Multiple Myeloma
For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not ne ...
FiercePharma23h
Roche's breast cancer entrant Itovebi bolsters clinical profile with overall survival win
Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...
The American Journal of Managed Care1d
FDA Approves Trastuzumab Deruxtecan for HER2-Low/Ultralow Breast Cancer
The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.